AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04375930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION
Description: STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION: It is consist of skills, discharge, compilation and algorithm education.
Study NCT00218790 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cool Dialysate
Description: Decreased temperature of the dialysis bath
Study NCT04375930 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: It consists of only skills and discharge education
Study NCT02489019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Sodium chloride will be used as a placebo comparator in this trial
Study NCT00898404 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01117012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Study NCT02043236 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy bones pamphlet
Description: written educational material
Study NCT02043236 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bone Health Care Coordinator
Description: The Bone Health Care Coordinator reviews educational materials with participant and facilitates ordering BMD.
Study NCT01081158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: SCH 900518 Biologic: Peginterferon alfa-2b
Description: Drug: SCH 900518~Biologic: Peginterferon alfa-2b~Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days~Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly.
Study NCT01081158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)
Description: Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension + ritonavir (200 mg BID) (2-100 mg oral capsules) for 7 days.~Period 2: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension+ ritonavir (200 mg BID) (2-100 mg oral capsules) + PegIntron (1.5 µg/kg QW) for 14 days.
Study NCT01081158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)
Description: Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1, Amorphous SCH 900518 (400 mg) or placebo BID administered as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) for 7 days.~Period 2, SCH 900518 (400 mg) or placebo BID as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) +PegIntron (1.5 µg/kg SC QW) for 14 days.
Study NCT02043236 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Letter to GP
Description: The letter to the General Practitioner contains information about the study, recommendations for bone health, guidelines of Osteoporosis Canada, and the identical educational material that the participant received.
Study NCT02489019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl is a synthetic opioid analgesic that will be used as the experimental intervention in this trial
Study NCT04309214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCT fats
Description: Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period
Study NCT03685045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Campaign days
Description: Participants who consent will complete study procedures (Hep C test, fibroscan, questionnaire, clinical assessment) and followed up through medical record review.
Study NCT00356057 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Protos DR/CLS and Stratos LV CRT pacemakers
Description: Protos DR/CLS is a dual chamber pacemaker with CLS rate adaption, Stratos LV is a biventricular pacemaker with accelerometer based rate adaption
Study NCT04011124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: single dose on Day 1 and Day 12
Study NCT04011124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: QD on Day 5-14 for 10 days
Study NCT03516734 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron fortified lentils
Description: Lentils will be iron-fortified using NaFeEDTA iron fortificants
Study NCT03516734 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non Iron-fortified lentils
Description: Non-fortified lentils will be provided
Study NCT03516734 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Intake
Description: No lentils will be provided.
Study NCT01888861 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid
Description: the patients in this arm receive 900mg alpha-lipoic acid through NG tube.
Study NCT01888861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the patients in this arm were received 900mg placebo through NG tube.
Study NCT01254448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5619
Description: Group 1: 25 mg TC-5619 administered once daily for 28 days. Group 2: 50-150 mg TC-5619 administered once daily for 10 days.
Study NCT00080886 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rituximab
Study NCT00080886 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: carmustine
Study NCT00080886 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cytarabine
Study NCT00080886 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: etoposide
Study NCT00080886 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: melphalan
Study NCT00080886 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: autologous bone marrow transplantation
Study NCT00080886 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: peripheral blood stem cell transplantation
Study NCT03485092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: Empagliflozin 10mg tablets for oral self administration once a day
Study NCT03485092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo tablets for oral self administration once a day
Study NCT03654755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002
Description: Daily dose of ASN002 for up to 110 weeks
Study NCT02551666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance recovery training
Description: Participants will practice recovering their balance after a perturbation similar to tripping while walking. Each of these 'balance recovery training' sessions will last approximately 30 minutes, and will be performed 3 times per week for 4 weeks.
Study NCT02551666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi exercise
Description: Participants will perform Tai Chi exercises (Yang short form) for 30 minutes, 3 times a week for 4 weeks. Each session will be led by an experienced Tai Chi instructor.
Study NCT02563821 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient Controlled Epidural Analgesia for third trimester termination of preganancy analgesia
Study NCT02563821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Study NCT02563821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sufentanil
Study NCT02563821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine
Study NCT01254448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group 1: matching placebo administered once daily for 28 days. Group 2: matching placebo administered once daily for 10 days.
Study NCT03278548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volulyte 6%
Description: Solution for infusion
Study NCT01589510 — intervention group
Intervention type: DRUG
Intervention: bimatoprost 0.01% ophthalmic solution
Description: Bimatoprost 0.01% ophthalmic solution (Lumigan® 0.01%) as prescribed by physician per standard practice for up to 14 weeks.
Study NCT01754675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soccer
Description: Watching the soccer match at the time that the favorite team is playing
Study NCT01754675 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Movie
Description: Watching a movie at the time that the favorite team is playing
Study NCT01098825 — intervention group
Intervention type: OTHER
Intervention: web-based survey
Description: Anonymous web-based survey
Study NCT02000518 — intervention group
Intervention type: RADIATION
Intervention: external beam radiotherapy
Study NCT03278548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ionolyte
Description: Solution for infusion
Study NCT02563821 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: epidural catheter
Study NCT02931045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Comparison of ticagrelor with another antiplatelet drug (clopidogrel)
Study NCT02931045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Comparison of clopidogrel with another antiplatelet drug (ticagrelor)
Study NCT02742129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Sodium Nitrite
Description: Inhaled, nebulized inorganic sodium nitrite vs. inhaled, nebulized placebo at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
Study NCT02742129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized Sodium Nitrite
Description: Inhaled, nebulized inorganic sodium nitrite vs. inhaled, nebulized placebo at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
Study NCT02742129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inhaled, nebulized placebo vs. inhaled, nebulized inorganic sodium nitrite at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
Study NCT02742129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled, nebulized placebo vs. inhaled, nebulized inorganic sodium nitrite at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
Study NCT04460781 — intervention group
Intervention type: BIOLOGICAL
Intervention: Flublok Quadrivalent influenza vaccine RIV4
Description: Route of administration: Intramuscular
Study NCT04460781 — intervention group
Intervention type: BIOLOGICAL
Intervention: Standard-dose quadrivalent inactivated influenza vaccine SD-IIV4
Description: Route of administration: Intramuscular
Study NCT04361500 — intervention group
Intervention type: DEVICE
Intervention: Seraph 100
Description: Seraph 100 therapy during a COVID-19 infection
Study NCT03856684 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-sampling kit sent at home
Description: Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory.
Study NCT03856684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-sampling kit sent at home + SMS reminder
Description: Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~After 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~* the receipt of the vaginal self-sample at the laboratory~* the performance of a pap smear~* Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory.
Study NCT03856684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter offering a self-sampling kit on request+ SMS reminder
Description: Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (kit provided on request) or to perform a pap smear.~Women are invited to ask the kit online, on our website.~For the women who ask the kit, after 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~* the receipt of the vaginal self-sample at the laboratory~* the performance of a pap smear~* Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory.
Study NCT03856684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS offering a self-sampling kit on request+ SMS reminder
Description: Selected women receive a SMS inviting them to ask a vaginal self sampling kit to perform a sample at home and send it to a laboratory (kit provided on request).~Women are invited to ask the kit by answering 1 by SMS.~For the women who ask the kit, after 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~* the receipt of the vaginal self-sample at the laboratory~* the performance of a pap smear~* Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory.
Study NCT01722565 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic abdominoperineal resection with a lightweight mesh (polypropylene and poliglecaprone 25)
Study NCT01912274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pracinostat
Description: Elderly newly diagnosed patients will all receive pracinostat
Study NCT01912274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Elderly newly diagnosed patients will all receive azacitadine
Study NCT01745211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser
Description: 755nm Alexandrite laser with array handpiece
Study NCT02696603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participant self-assessment surveys
Description: At enrollment, participants are asked to complete a baseline health history and a participant-reported symptom inventory. Thereafter, participants are asked to respond to commonly used questions that assess Parkinson Disease symptoms and quality of life at regular intervals.
Study NCT02696603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phonation
Description: Participants are asked to record themselves saying Aaah for 10 seconds using the iPhone microphone. This activity is designed to assess vocal features, including vocal tremor. The investigators extract features from the digital audio signals of these sustained phonations. The investigators apply feature selection and classifier algorithms and analyze these phonations using methods similar to those employed in the Parkinson Voice Initiative.
Study NCT02696603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait and balance
Description: Participants are asked to walk back and forth for 30 seconds and then stand still for 30 seconds. Gait and balance are measured by gyroscope and accelerometer sensors. The investigators examine step-dependent and sequence-dependent features from these sensors. The investigators apply feature selection and classifier algorithms to analyze these data.
Study NCT02696603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory
Description: Participants are asked to complete a visuospatial short-term memory game related to the Corsi block tapping test \[Corsi, P.M. (1972)\] as adapted by Kate Possin, PhD of the University of California San Francisco Memory and Aging Center (personal communication, 2015). In this activity, participants are presented with a grid of objects that change color in a set pattern. Participants are then asked to tap the objects in that same pattern. The investigators assess the sequence length completed.
Study NCT02696603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dexterity
Description: Participants are asked to tap on the phone screen with alternating fingers. This test can be done with either or both hands. The investigators record the rhythm, speed, and location of these taps using the touch sensors of the iPhone screen. The investigators assess participant dexterity through a combination of steadiness, speed, and tap precision.
Study NCT02696603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participant open-response writing
Description: Qualitative participant feedback is used to assess participant engagement with, understanding of, and acceptance of app-based research.
Study NCT02696603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parkinson mPower mobile application
Description: Participants complete all described behavioral interventions via a dedicated iPhone app, Parkinson mPower.
Study NCT04157881 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: RABEprazole 20 Mg Oral Delayed Release Tablet
Description: Absorption of APO-Dabigatran measured with and without influence of rabeprazole
Study NCT04157881 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: APO-Dabigatran 150mg
Description: Absorption of APO-Dabigatran post single dose
Study NCT04865666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: movr mHealth App
Description: The exercises prescribed through the movr app were accompanied with videos, images, and detailed instructions on how to complete them. These exercises consisted of basic movement and mobility patterns and are designed to promote functional movement. Participants were instructed to complete a total of four 'Minis' and two workout 'Builder' sessions per week. Workout Builders are designed to be longer exercise sessions tailored to the user's desired exercise time (15, 30, 45 or 60 min), equipment available (TRX Band, kettlebell, chin-up bar, dumbbells, foam roller, or none), target body region (lower, upper, or whole body), and specific exercise goal ('get sweaty,' 'build strength,' or 'develop mobility'). Version 3.6 of the movr app was used at the start of data collection and was updated to Version 4.1 over the course of the trial. No significant changes were made to the app or to the exercise prescription functionality throughout those updates.
Study NCT01778998 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MICS-group
Description: Micro incision cataract surgery is done
Study NCT01778998 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SICS-group
Description: small incision cataract surgery is done
Study NCT01778998 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SICS pre-cut
Description: Small incision cataract surgery with pre-cut is done
Study NCT01778998 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SICS stab-incision
Description: Small incision cataract surgery with stab-incision is done
Study NCT00844103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8566
Description: 10ml oral solution administered once a day over 10 days. Specific dose will be selected by the safety review committee
Study NCT00844103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10ml oral solution administered once a day over 10 days.
Study NCT00386490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larazotide acetate
Description: capsule for oral administration
Study NCT02394808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day
Study NCT02394808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day
Study NCT02394808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lotrafilcon B
Description: One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day
Study NCT02394808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day
Study NCT03559192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-67953964
Description: JNJ-67953964 10 mg will be administered as two 5-mg capsules orally once daily.
Study NCT03559192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as 2 capsules orally once daily.
Study NCT03559192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as 2 capsules orally once daily.